Sabarep (YP001) / York Pharmaceuticals - LARVOL DELTA

Lipopeptides and antibiotics from a marine Bacillus pumilus mediate a potential "catch and kill" effect on pathogenetic Vibrio parahaemolyticus. (PubMed, mSystems) - "In this study, we investigated the chemical interactions between two marine bacterial colonies, Vibrio parahaemolyticus PSU5429 and Bacillus pumilus YP001...This study shows that the spatial localization of natural products shapes microbial behavior on surfaces and provides a general, scalable workflow that maps chemistry to phenotype. Beyond this case, the approach can be applied broadly to understand and, ultimately, tune microbial interactions relevant to marine ecosystems, aquaculture health, and microbiome engineering."

Journal

A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD (ASH 2018) - P1; "Treatment response and overall survival rates are encouraging compared to previously published outcomes. The Cohort B primary evaluation period is expected to be completed by September 2018, and progression to a Phase II trial in this clinically challenging disease will then be considered."

P1 data • Biosimilar • Graft versus Host Disease • Hematological Disorders • Immunology • Neutropenia • Transplantation